An interventional study of Afluxin® and Placebo in Gastroesophageal Reflux Disease (GERD), sponsored by Devintec Sagl. Recruiting at 7 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Devintec Sagl · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Gastroesophageal Reflux with a site in Italy — 12 open to participants now, 14 under way, none of them phase 3. Gastroesophageal Reflux · Italy.
Among the 78 studies in Gastroesophageal Reflux with a site in Italy, this one is the 14th largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 69th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →12 of the 78 studies in Gastroesophageal Reflux with a site in Italy are open now. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Healthy volunteers
United Pharmaceuticals · Sites in Italy, Belgium, France and 1 more country
Ages 2 wk–4 mo
Implantica CE Reflux Ltd. · Sites in Italy, Germany, Norway and 1 more country
Ages 18+
Medtronic Cardiovascular · Sites in Italy, Denmark, France and 5 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 3 mo–24 mo
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 11 · Phase 4 5
First in 1995; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 208 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 80 across the 48 interventional studies, 139 across the 30 observational. Of the 52 that completed or were terminated, 12 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 78 have an industry lead sponsor. The 10 most frequent:
Devintec Sagl is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Devintec Sagl has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
4 of the studies in Gastroesophageal Reflux with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04358146United PharmaceuticalsStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR) | 2026-12-03 |
| NCT06984484Devintec SaglPerformance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease | 2027-01 |
| NCT07036627University of BariIntestinal Microbiota After PPI Treatment | 2027-01-01 |
| NCT07790549Liaquat University of Medical & Health SciencesMirgeal® Gel as Add-on Therapy to Esomeprazole in Adults With Non-Erosive Gastroesophageal Reflux Disease | 2027-01-29 |
Add all 4 to your calendar (.ics) → With an account.
Among the 78 studies in Gastroesophageal Reflux with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gastroesophageal Reflux Disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus, causing irritation and inflammation. GERD is categorized into Nonerosive Reflux Disease (NERD), Erosive Esophagitis (EE), and Barrett's esophagus (BE). Common symptoms include heartburn and acid regurgitation. Lifestyle factors such as smoking, obesity, and Helicobacter pylori infection can increase the risk of developing GERD. The clinical management of GERD typically involves Proton Pump Inhibitors (PPIs) therapy, which, although effective, may not benefit all patients and can be associated with long-term risks. The American College of Gastroenterology (ACG) suggests PPIs discontinuation or on-demand therapy for uncomplicated GERD after an 8-week trial. However, evidence indicates that PPIs are used more frequently, often long-term and in high doses, and not necessarily according to recommendations. Moreover, the availability of Over-The-Counter (OTC) PPIs has led to prolonged use by patients without medical guidance. Concerns have been raised due to potential side effects of long-term PPIs use, including enteric, respiratory, and urinary tract infections, as well as an increased risk of vitamin and mineral deficiencies and osteoporosis.
Alternatives to PPIs include Histamine-2 Receptor Antagonists (H2RAs), antacids and alginate-based formulations. Among OTC treatments, medical devices formulated with natural components are also gaining attention for their potential performance and tolerability in managing mild to moderate GERD symptoms. These alternatives could address the unmet needs of NERD patients, especially those with a low response to PPIs treatment and provide an option without the potential side effects of prolonged PPIs use. Afluxin® is a class III medical device, containing functional substances (tamarind seed polysaccharide, pea protein and polyacrylic acid), formulated for the treatment of mild to moderate GERD. Preclinical data have shown that Afluxin® is able to create a protective barrier over the gastroesophageal epithelium, preventing reflux damage. In vitro studies suggest that Afluxin® effectively binds to the esophageal and gastric mucosa, reducing abnormal permeability caused by acid reflux. Moreover, in vivo evidence shows that Afluxin® can increase gastric pH, reduce epigastric pain, esophageal damage, and inflammatory markers associated with GERD. Given the encouraging results obtained in preclinical investigations, this study is designed to provide clinical evidence to support the performance and safety of Afluxin® in reducing gastrointestinal symptoms of patients with mild to moderate GERD in a multicenter, randomized, double-blind, parallel-group, Afluxin® stick pack vs. inactive control clinical investigation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a:
Patients using any drug that could affect symptoms or affecting the gastrointestinal tract during the last week prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Afluxin® is a medical device not CE marked yet. According to the Annex VIII of MDR 2017/745 it belongs to class III (Rule 21). Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed. Afluxin® does not contain any medicinal substances, human or animal tissues or their derivatives, or other biologically active substances coming in contact with the patient. The composition of one stick pack of Afluxin® is the following: purified water, isolated pea proteins, tamarind seed polysaccharide (Tamarindus indica L.), polyacrylic acid, propyl 4-hydroxybenzoate sodium salt, sodium methylparaben, strawberry aroma, mint aroma, sodium hydroxide, sucralose.
Device: Afluxin®
Placebo is an inactive preparation designed to match the active treatment in taste and have a similar color (white-transparent) to Afluxin®.
Drug: Placebo
Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
Inactive control stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
Assess the superiority of a 7-day treatment course with Afluxin® over inactive control in terms of difference between treatment groups in terms of proportion of responders
The primary endpoint is the difference between treatment groups (Afluxin® and placebo) in terms of proportion of responders, defined as patients who report a reduction in the GERD dimension of the RDQ (Reflux Disease Questionnaire) equal to 1.5 points (clinically significant difference, according to Wilkinson et al., 2019), between baseline and the end of the 7-day treatment. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The questionnaire consists of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia. In this study the two subscales for heartburn and regurgitation will be combined into the GERD dimension. Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).
Time frame: From enrollment to the end of the 7-day treatment
RDQ GERD dimension, including single item scores
GERD dimension evaluated through the RDQ (Reflux Disease Questionnaire) and evaluation of the single item scores, at the baseline and at the end of the 7-day treatment. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The self-assessed questionnaire will consist of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia. The two subscales for heartburn and regurgitation will be combined into the GERD dimension. Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).
Time frame: Baseline and at the end of the 7-day treatment
RDQ dyspepsia dimension total and single item scores
Dyspepsia dimension evaluated through the RDQ (Reflux Disease Questionnaire) total and single item scores, at the baseline and at the end of the 7-day treatment. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The self-assessed questionnaire will consist of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia (burning/pain in the upper stomach). Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).
Time frame: Baseline and at the end of the 7-day treatment
Total and single item scores of the Reflux Symptom Index (RSI)
Total and single item scores of the Reflux Symptom Index (RSI) at baseline and at the end of the 7-day treatment, assessing the severity of Laryngopharyngeal Reflux (LPR) symptoms. The RSI validated in Italian language, will be used for the evaluation of LPR symptoms that patients have been experiencing within the last month. The RSI examines 9 items, to be scored from 0 (no problem) to 5 (severe problem), with a higher score indicating a higher severity of the symptom (range of total score: 0-45) .
Time frame: Baseline and at the end of the 7-day treatment
Severity of GERD cardinal symptoms (i.e., heartburn and regurgitation)
Severity of GERD cardinal symptoms (i.e., heartburn and regurgitation) throughout the 7-day treatment, as self-assessed daily by patients using a 7-point Likert scale ranging from 1 = no discomfort to 7 = very severe discomfort.
Time frame: Throughout the 7-day treatment
Severity of LPR symptoms (i.e., hoarseness/clearing the throat and troublesome cough)
Severity of (Laryngopharyngeal Reflux) LPR symptoms (i.e., hoarseness/clearing the throat and troublesome cough) throughout the 7-day treatment, as self-assessed daily by patients using a 7-point Likert scale ranging from 1 = no discomfort to 7 = very severe discomfort.
Time frame: Throughout the 7-day treatment
Number and percentage of patients with occurrence of symptoms during the night
Number and percentage of patients with occurrence of symptoms during the night throughout the 7-day treatment
Time frame: Throughout the 7-day treatment
Mean time to alleviation of symptoms following treatment administration
Mean time to alleviation of symptoms following treatment administration throughout the 7-day treatment, as self-assessed daily by patients
Time frame: Throughout the 7-day treatment
Number and percentage of patients with complete remission of symptoms
Number and percentage of patients with complete remission of symptoms at the end of the 7-day treatment, defined as an RDQ (Reflux Disease Questionnaire) GERD dimension total score = 0 points. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The self-assessed questionnaire will consist of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia. Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).
Time frame: At the end of the 7-day treatment
Mean score on the self-report measure Patient's Global Impression of Change (PGI-C)
Mean score on the self-report measure Patient's Global Impression of Change (PGI-C) at the end of the 7-day treatment, assessing the patient's overall perceived change in their condition. The self-report measure PGI-C will be used to assess the overall perceived improvement at the end of the 7-day treatment. Patients will reply to the general statement "Since the start of the study, my overall status is'", using the following 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.
Time frame: At the end of the 7-day treatment
Number and percentage of patients who take prohibited medications
Number and percentage of patients who take prohibited medications (Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, antiacid, alginates or medical devices made of substances).
Time frame: Throughout the 7-day treatment
Patient's compliance with treatment
Patient's compliance with treatment protocol, in terms of adherence to the instructions and recommendations of the study treatment protocol. The information are recorded on the patient's diary and reviewed by the investigators. Patient differences in % compliance between the two treatments will be calculated.
Time frame: Throughout the 7-day treatment
Patient's satisfaction with treatment
Patient's satisfaction with treatment, as self-assessed by the patient using a 5-point response scale, at the end of the 7-day treatment. At the end of the 7-day treatment the patient will record his/her opinion of satisfaction with treatment in the e-diary, answering the question: "How satisfied are you with the study treatment you received?" with a 5-point response scale (1=unsatisfied, 2=somewhat unsatisfied, 3=neutral, 4=somewhat satisfied, 5=satisfied).
Time frame: At the end of the 7-day treatment
Safety: adverse events and device deficiencies
Incidence and type of AEs and DDs continuously monitored during the study
Time frame: Throughout the 7-day treatment
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.
Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 18 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Devintec Sagl